Intra-Cellular Therapies Stock (NASDAQ: ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) Stock, Quote.Headers.trade-ideas

Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Robinhood's Strong Crypto Surge

News

Upgrades

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

HOOD

HUBB

ITCI

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

NVIDIA's Nerve-Wracking Ride

Trading Ideas

CHUY

HSIC

NVDA

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Bilibili_world

Movers

AMKR

BILI

BRFS

IBRX

IRTC

OLLI

RKLB

TALO

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%).

China&#39;s Bilibili And Ollie&#39;s Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies Inc

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and maintains $130 price target.</p>


Reiteration

Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target

<p>In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725645611_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Intra-Cellular Therapies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>A Deep Dive into Intra-Cellular Therapies's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of <strong>46.44%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-10.06%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.86%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.57%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.02</strong>, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Intra-Cellular Therapies

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a></p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585939c1ee7bf600010fe945/nigel-coe">Wolfe Research analyst Nigel Coe</a> upgraded the rating for <strong>Eaton Corporation plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) from Underperform to Peer Perform. Eaton shares fell 1.1% to close at $285.72 on Thursday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Nicole Deblase upgraded <strong>Hubbell Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from Hold to Buy and raised the price target from $431 to $441. Hubbell shares fell 1.2% to close at $370.42 on Thursday. See how other analysts view this stock.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ffc5e0662ba1f0001bb0ac5/nick-lai">JP Morgan analyst Nick Lai </a>upgraded the rating for<strong> NIO Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Overweight and raises the price target from $5.3 to $8. NIO shares gained 14.4% to close at $4.85 on Thursday. <a href="https://www.benzinga.com/quote/nio/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Charles Duncan upgraded <strong>Intra-Cellular Therapies, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and boosted the price target from $68 to $92. Intra-Cellular Therapies shares declined 0.3% to close at $72.42 on Thursday. S<a href="https://www.benzinga.com/quote/itci/analyst-ratings">ee how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/630f381cec9f420001742995/benjamin-budish">Barclays analyst Benjamin Budish</a> upgraded the rating for <strong>Robinhood Markets, In</strong>c. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Equal-Weight and raised the price target from $18 to $20. Robinhood shares gained 2.9% to close at $19.67 on Thursday. <a href="https://www.benzinga.com/quote/hood/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying HOOD stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png" alt="" class="wp-image-534479" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12.png 1311w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>


<p>Piper Sandler  analyst Charles Duncan   upgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and raises the price target from $68 to $92.</p>


Piper Sandler Upgrades Intra-Cellular Therapies to Overweight, Raises Price Target to $92

<p>JP Morgan  analyst Jessica Fye   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $79 to $81.</p>


JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81

<p>RBC Capital  analyst Brian Abrahams   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and lowers the price target from $107 to $106.</p>


RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $106

<p>Cantor Fitzgerald  analyst Charles Duncan   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $120 to $130.</p>


Cantor Fitzgerald Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $130

<p>UBS  analyst Ashwani Verma   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and lowers the price target from $83 to $79.</p>


UBS Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $79

<p>Goldman Sachs  analyst Corinne Jenkins   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and lowers the price target from $77 to $74.</p>


Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $74

<p>Needham  analyst Ami Fadia   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and maintains $100 price target.</p>


Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

<p>9 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.0, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 2.41% from the previous average price target of $96.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723035647_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Intra-Cellular Therapies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Intra-Cellular Therapies's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>All You Need to Know About Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Intra-Cellular Therapies: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>52.9%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-10.53%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.56%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.07%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)

Management

Intra-Cellular Therapies Announced That Sanjeev Narula Will Join The Company On August 12, 2024, And Will Serve As Executive Vice President, Chief Financial Officer

Guidance

Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $650M-$680M

<p>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent.  The company reported quarterly sales of $161.400 million which beat the analyst consensus estimate of $157.880 million by 2.23 percent.  This is a 45.68 percent increase over sales of $110.792 million the same period last year.</p>


Earnings

Earnings Beats

Intra-Cellular Therapies Q2 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $161.400M Beat $157.880M Estimate

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.</p>
<ul>
<li>Goldman Sachs cut the price target for <strong>Lennar Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for <strong>NVIDIA Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for <strong>Chuy&#8217;s Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from $38 to $37.5. Wedbush analyst Nick Setyan downgraded the stock from Outperform to Neutral. Chuy&#8217;s shares fell 0.7% to close at $37.08 on Friday. <a href="https://www.benzinga.com/quote/CHUY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities decreased <strong>Comerica Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) price target from $55 to $53. Truist Securities analyst Brandon King downgraded the stock from Buy to Hold. Comerica shares fell 10.5% to close at $50.42 on Friday. <a href="https://www.benzinga.com/quote/CMA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities boosted the price target for <strong>Redwire Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) from $6 to $8. B. Riley Securities analyst Mike Crawford downgraded the stock from Buy to Neutral. Redwire shares fell 0.9% to close at $6.98 on Friday. <a href="https://www.benzinga.com/quote/RDW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised <strong>International Flavors &amp; Fragrances Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) price target from $95 to $115. Stifel analyst Mark Astrachan upgraded the stock from Hold to Buy. International Flavors shares fell 1% to close at $95.67 on Friday. <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised <strong>Henry Schein, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $81 to $92. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. Henry Schein shares fell 0.5% to close at $70.34 on Friday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut <strong>Alaska Air Group, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) price target from $75 to $70. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. Alaska Air shares gained 1.8% to close at $37.93 on Friday. <a href="https://www.benzinga.com/quote/ALK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut <strong>Domino&#8217;s Pizza, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $500. Deutsche Bank analyst Lauren Silberman maintained a Buy rating. Domino&#8217;s shares fell 1.2% to close at $404.17 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased <strong>Abercrombie &amp; Fitch Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) price target from $167 to $194. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Abercrombie &amp; Fitch shares gained 1% to close at $158.51 on Friday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p><strong>Check This Out: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/07/39876945/s-p-500-logs-worst-weekly-decline-since-april-investor-optimism-falls-further">S&amp;P 500 Logs Worst Weekly Decline Since April; Investor Optimism Falls Further</a></strong></li>
</ul>


<p>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 1.96% from the previous average price target of $97.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721653252_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intra-Cellular Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Intra-Cellular Therapies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Get to Know Intra-Cellular Therapies Better</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Intra-Cellular Therapies: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>52.9%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-10.53%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.56%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-2.07%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies

<p>Needham  analyst Ami Fadia   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and raises the price target from $94 to $100.</p>


Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100

<p>UBS  analyst Ashwani Verma   downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Buy to Neutral and lowers the price target from $85 to $83.</p>


Downgrades

UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83

In a report released yesterday, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report),...

Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst

Marc Goodman, an analyst from Leerink Partners, reiterated the Buy rating on Intra-Cellular Therapies (ITCI – Research Report). The associated pric...

Buy Rating Affirmed for Intra-Cellular Therapies Amid Strong Sales and Expansion Potential

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), S...

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)

Executive reshuffles: Uranium Energy, Nutrien and Logitech International Companies in focus

Invesco Main Street Mid Cap Fund Q2 2024 Review

Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), retaining the price targ...

Intra-Cellular Therapies: A Buy Rating on Strong Commercial Performance and Robust Pipeline

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

Peaking Back In On Intra-Cellular Therapies

Piper Sandler ups Intra-Cellular to overweight, cites Caplyta potential

Stock moves reflect downgrade for US economic growth outlook - Goldman

ABBV

ADSK

APPF

ASGN

BEPC

BIIB

BILL

CACI

CAVA

CNMD

CWST

DASH

DAVA

DECK

DOCU

EYPT

FBIN

FTNT

GKOS

GLBE

INSP

IONS

IPGP

JAZZ

LBRDK

LECO

LGIH

LOGI

MANH

MCHP

MNST

MPWR

MRVL

MSTR

NBIX

ORCL

PCTY

PINS

PLTR

PODD

POOL

PRCT

RGEN

ROKU

RXST

SMCI

SPSC

SPXU

SRPT

STEM

TREX

TRGP

TRMB

UPRO

VERX

VLTO

XPEL

ZBRA

Health Care

Press Releases

General

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Intra-Cellular Therapies

Intra-Cellular Therapies (ITCI) Forecast

Intra-Cellular Therapies (NASDAQ:ITCI) Stock, Quote.Headers.trade-ideas